CRISPR Gene Therapy Patents: The Legal Battle Reshaping Biotechnology

The ongoing patent disputes surrounding CRISPR gene editing technology continue to reshape the biotechnology industry, with profound implications for innovation, patient access, and intellectual property strategy. This article examines the current state of CRISPR patent litigation and its broader significance.

The foundational CRISPR-Cas9 patent battle between the Broad Institute and the University of California has generated over a decade of litigation across multiple jurisdictions. While the U.S. Patent Trial and Appeal Board ruled in favor of the Broad Institute for eukaryotic applications, the European Patent Office has taken different positions on several related patents.

Beyond the foundational patents, a second wave of IP disputes has emerged around:

Next-Generation Editing Tools: Base editing, prime editing, and epigenetic editing technologies have spawned their own patent landscapes, with multiple institutions claiming overlapping rights.

Therapeutic Applications: As CRISPR-based therapies move toward clinical deployment, composition-of-matter patents for specific therapeutic applications have become increasingly valuable and contested.

Agricultural Applications: CRISPR applications in agriculture face a different regulatory and IP landscape, with gene-edited crops subject to varying regulatory frameworks across jurisdictions.

Licensing Strategies: The complex patent landscape has led to creative licensing approaches, including patent pools, cross-licensing agreements, and humanitarian licensing provisions for developing country access.

The resolution of these disputes will significantly influence the pace and direction of gene therapy development, the accessibility of CRISPR-based treatments, and the broader IP strategies of biotech companies worldwide.